Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.08 USD
Change Today +0.03 / 0.98%
Volume 2.0M
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
$3.08
Previous Close
$3.05
Day High
$3.16
Day Low
$2.99
52 Week High
07/1/15 - $4.67
52 Week Low
10/13/14 - $1.76
Market Cap
487.1M
Average Volume 10 Days
2.5M
EPS TTM
$-0.23
Shares Outstanding
158.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

42 Employees
Last Reported Date: 03/11/15
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $656.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $381.4K
Executive Vice President of Development and T...
Total Annual Compensation: $396.1K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $326.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $367.8K
Compensation as of Fiscal Year 2014.

geron corp (GERN) Key Developments

Geron Corporation Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Geron Corporation announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported license fees and royalties revenue of $251,000 compared with $341,000 for the same period a year ago. Loss from operations was $9,479,000 compared with $8,663,000 for the same period a year ago. Net loss was $9,356,000 or $0.06 per basic and diluted share compared with $8,734,000 or $0.06 per basic and diluted share for the same period a year ago. For the six months, the company reported license fees and royalties revenue of $788,000 compared with $815,000 for the same period a year ago. Loss from operations was $18,935,000 compared with $17,394,000 for the same period a year ago. Net loss was $18,671,000 or $0.12 per basic and diluted share compared with $17,174,000 or $0.11 per basic and diluted share for the same period a year ago.

Geron Mulls Acquisitions

Geron Corporation (NasdaqGS:GERN) intends to pursue acquisitions. "Our business development efforts continue, as we seek to identify and acquire and/or in-license other oncology products, programs or companies," said John A. Scarlett, Geron's President and Chief Executive Officer.

Geron Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Geron Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $9,456,000, net loss of $9,315,000 or $0.06 loss per share on license fees and royalties of $537,000 against loss from operations of $8,731,000, net loss of $8,440,000 or $0.06 loss per share on license fees and royalties of $474,000 for the same period a year ago. The increase in interest and other income in 2015 compared to 2014 was due to higher cash and investment balances in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.08 USD +0.03

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $2.95 USD +0.12
Neuralstem Inc $1.48 USD +0.13
Ocata Therapeutics Inc $3.77 USD -0.21
ReNeuron Group PLC 5.63 GBp +0.25
StemCells Inc $0.39 USD +0.0055
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 428.2x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 305.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.